Subcutaneous Immune Globulin (Human) (Hizentra)
ApprovedCompleted 2 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Primary Immune Deficiency
Conditions
Primary Immune Deficiency, Secondary Immune Deficiency
Trial Timeline
Mar 15, 2016 → Jan 30, 2018
NCT ID
NCT02711228About Subcutaneous Immune Globulin (Human) (Hizentra)
Subcutaneous Immune Globulin (Human) (Hizentra) is a approved stage product being developed by CSL for Primary Immune Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT02711228. Target conditions include Primary Immune Deficiency, Secondary Immune Deficiency.
What happened to similar drugs?
20 of 20 similar drugs in Primary Immune Deficiency were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02711228 | Approved | Completed |
Competing Products
20 competing products in Primary Immune Deficiency